Mary Wilson
Well-known member
Published: June 10, 2023
DOI: https://doi.org/10.1016/j.lansea.2023.100234
Sonjit Kumar Chakrovorty,a,d K. M. Amran Hossain,b,d Rubayet Shafin,c Shameem Ahammad,a and Iqbal Kabir Jahida,∗
The clinical definition of symptom sequelae of COVID- 19 changed over time. Till March 2021, ongoing symp- toms for more than four weeks were classified as post- COVID-19 symptoms (PCS),1 later, on October 2021, the WHO working group defines post-COVID-19 con- dition (PCC)2 as the ongoing symptoms of COVID-19 or newly developed symptoms noted after twelve weeks of initial SARS-CoV-2 infection and these symptoms persist for a minimum of two months, and no other medical diagnosis can explain these symptoms. Several studies have demonstrated the prevalence of PCS as 22.4%, 51%, and 43%, in Bangladeshi,3 Asian4, and Global4 populations respectively. The prevalence of PCC is still in a dilemma because none of the reported symptoms matches WHO criteria.2 A meta-analysis4 of symptoms diagnosed PCC as symptoms persistent after 4 weeks of COVID-19, other Epidemiological studies from Bangladesh,3 India,5 United Kingdom,6 and the United States7 diagnosed PCC with symptoms noted after 12 weeks of COVID-19 but not persistent for a minimum of two months duration. So, there is a research gap in the epidemiology of PCC according to WHO criteria. PCC causes relapsing, remittent episodes of symptoms causing episodic disabilities,4,6 but the interaction between disease and disability induced by PCC is still unclear. ...
https://www.thelancet.com/action/showPdf?pii=S2772-3682(23)00094-X
DOI: https://doi.org/10.1016/j.lansea.2023.100234
Sonjit Kumar Chakrovorty,a,d K. M. Amran Hossain,b,d Rubayet Shafin,c Shameem Ahammad,a and Iqbal Kabir Jahida,∗
The clinical definition of symptom sequelae of COVID- 19 changed over time. Till March 2021, ongoing symp- toms for more than four weeks were classified as post- COVID-19 symptoms (PCS),1 later, on October 2021, the WHO working group defines post-COVID-19 con- dition (PCC)2 as the ongoing symptoms of COVID-19 or newly developed symptoms noted after twelve weeks of initial SARS-CoV-2 infection and these symptoms persist for a minimum of two months, and no other medical diagnosis can explain these symptoms. Several studies have demonstrated the prevalence of PCS as 22.4%, 51%, and 43%, in Bangladeshi,3 Asian4, and Global4 populations respectively. The prevalence of PCC is still in a dilemma because none of the reported symptoms matches WHO criteria.2 A meta-analysis4 of symptoms diagnosed PCC as symptoms persistent after 4 weeks of COVID-19, other Epidemiological studies from Bangladesh,3 India,5 United Kingdom,6 and the United States7 diagnosed PCC with symptoms noted after 12 weeks of COVID-19 but not persistent for a minimum of two months duration. So, there is a research gap in the epidemiology of PCC according to WHO criteria. PCC causes relapsing, remittent episodes of symptoms causing episodic disabilities,4,6 but the interaction between disease and disability induced by PCC is still unclear. ...
https://www.thelancet.com/action/showPdf?pii=S2772-3682(23)00094-X